Pay in 4 interest-free payments of $6.28 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
intravenous TB-4 Phase 1 safety and pharmacokinetics, no dose-limiting or serious adverse events (Ann N Y Acad Sci 2010;1194:223229): NCT00743769 On February 27, 2026, HHS Secretary Kennedy announced that GHK-Cu is among approximately 14 peptides expected to return to Category 1
Root Cause: Payers require the injection procedure code (CPT 96372) to be paired with a billable drug (e.g., J3301 for Kenalog) to validate the claim
None of this is individualized medical advice it is the documented research cadence
Supports fat metabolism, potentially assisting with weight loss goals when combined with exercise and a healthy diet
US$ 29.68
US$ 26.33
US$ 22.65
